Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis

L. McGurk 1, J. Mojsilovic-Petrovic 2,3, V. M. Van Deerlin 4, J. Shorter 5, R. G. Kalb 2,3, V. M. Lee 4, J. Q. Trojanowski 4, E. B. Lee 4,6 and N. M. Bonini 1*

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating and fatal motor neuron disease. Diagnosis typically occurs in the fifth decade of life and the disease progresses rapidly leading to death within ~2–5 years of symptomatic onset. There is no cure, and the few available treatments offer only a modest extension in patient survival. A protein central to ALS is the nuclear RNA/DNA-binding protein, TDP-43. In > 95% of ALS patients, TDP-43 is cleared from the nucleus and forms phosphorylated protein aggregates in the cytoplasm of affected neurons and glia. We recently defined that poly(ADP-ribose) (PAR) activity regulates TDP-43-associated toxicity. PAR is a posttranslational modification that is attached to target proteins by PAR polymerases (PARPs). PARP-1 and PARP-2 are the major enzymes that are active in the nucleus. Here, we uncovered that the motor neurons of the ALS spinal cord were associated with elevated nuclear PAR, suggesting elevated PARP activity. Veliparib, a small-molecule inhibitor of nuclear PARP-1/2, mitigated the formation of cytoplasmic TDP-43 aggregates in mammalian cells. In primary spinal-cord cultures from rat, Veliparib also inhibited TDP-43-associated neuronal death. These studies uncover that PAR activity is misregulated in the ALS spinal cord, and a small-molecular inhibitor of PARP-1/2 activity may have therapeutic potential in the treatment of ALS and related disorders associated with abnormal TDP-43 homeostasis.

Keywords: ABT-888/Veliparib, Parp, Poly(ADP-ribose), PAR, PARylation, Motor neuron disease, primary neuron, TDP-43

Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease where the degeneration of upper and lower motor neurons leads to muscle atrophy, paralysis and death typically within ~2–5 years of disease onset [47]. In > 95% of ALS patients, the normally nuclear protein TDP-43 redistributes to the cytoplasm and forms phosphorylated aggregates in affected neurons and glia [45, 69, 84, 85]. The treatment options for ALS are bleak, most are palliative and address the well-being and comfort of the patient [38, 44, 82, 91]. The first FDA-approved drug was riluzole, an anti-glutamatergic that provides a ~2–3-month extension in patient survival [88, 95]. In the 20 years since, a gamut of treatments has been clinically tested, but most have failed to demonstrate therapeutic efficacy [9, 38, 88]. In 2017, the second FDA approval was granted to edaravone, an anti-oxidant which, when administered with riluzole, modestly reduces neurological decline in the early stages of disease [26, 39, 40, 92, 97]. Thus, uncovering molecular pathways that contribute to the decline and loss of motor neurons in ALS is imperative for the development and testing of new treatments.

Although the exact cause of ALS remains largely unknown, genetic factors contribute to ~5–10% of cases [65, 107]. Familial genes include SOD1, C9orf72, ATXN2 and TARDBP [28, 29, 89, 90, 104]. Several of the proteins mutated in ALS, including TDP-43 and Ataxin-2, are components of cytoplasmic stress granules [64], which are membraneless organelles that are comprised of translationally-arrested mRNA and associated proteins [4, 53]. In the ALS spinal cord, several stress-granule
proteins, such as TIA-1, eIF3, and PABPC-1, co-aggregate with phosphorylated TDP-43 inclusions [10, 66, 74]. Furthermore, manipulation of proteins that regulate the stress response is beneficial in animal and cellular models of ALS [8, 29, 35, 55, 58, 86, 98, 117]. Despite evidence implicating stress pathways in ALS, it is unclear whether they are cause or consequence of the disease process.

We identified Tankyrase, a poly(ADP-ribose) polymerase, or PARP, as a potent regulator of disease-associated features of TDP-43 in Drosophila and mammalian cell models of ALS [73]. PARPs are enzymes that catabolize NAD⁺ to sequentially add ADP-ribose subunits onto target proteins, generating polymers of poly(ADP-ribose) (PAR) [37]. PAR activity is often stress responsive and can serve as an upstream signaling molecule [41, 63, 68]. In mammals, the PARP superfamily consists of 17 enzymes, with the most abundant and well characterized being PARP-1 [67, 99]. In the nucleus, PARP-1 and PARP-2 regulate DNA damage, gene expression, and cell survival [18, 34, 41, 48, 67]. Here, we report that PAR levels are elevated in the nuclei of motor neurons in the spinal cord of ALS patients, and that a PARP-1/2 inhibitor is therapeutic in a rodent spinal-cord cellular model of TDP-43-associated toxicity. These findings implicate an alteration in PAR activity in ALS, and suggest that PARP-1/2 inhibitors, which are in use for cancer treatment, might be repurposed for TDP-43-associated disorders.

### Materials and methods

#### Clinical data and patient consent

Patient tissue was obtained from the Center for Neurodegenerative Disease Research (CNDR) Brain Bank at the University of Pennsylvania, brief details are provided in Tables 1 and 2. Patients were selected on the basis of having phosphorylated TDP-43 in motor neurons in the spinal cord. All patients pre-consented for autopsy as well as at time of death. Consent for autopsy was re-obtained from the next-of-kin in accordance with institutional review board guidelines of the University of Pennsylvania. The University of Pennsylvania Institutional Review Board reviewed and confirmed that the CNDR Neurodegenerative Disease Autopsy Brain Bank protocols meet the criteria for human-subjects research.

#### Immunohistochemistry

Tissue was examined by routine neuropathologic diagnostic methods, as described [36, 83, 85, 110]. Briefly, spinal-cord regions were fixed in 10% neutral buffered formalin and 6 µm thick sections were cut from paraffin-embedded tissue. After dewaxing and rehydration endogenous peroxidases were quenched in 30% H₂O₂ made up in methanol (30 min) and washed in running tap water (10 min). For antibodies requiring antigen retrieval (only anti-phosphorylated TDP-43) slides were incubated in a citrate based antigen retrieval (pH 6) buffer (Vector labs #H3300) (15 min at 99 °C) in an EZ-retriever microwave (BioGenex). Slides and solution

### Table 1 Patients with no known neurological disease

| #  | Diagnosis     | Sex | Age at Death (yr) | PMI (hr) | Brain weight (g) | ALS stage | Braak stage | Thal phase | CERAD | LBD |
|----|---------------|-----|-------------------|----------|-----------------|-----------|-------------|------------|-------|-----|
| 1  | normal        | M   | 47                | 12       | 1383            | 0         | I/II        | 0          | 0     | no  |
| 2  | normal        | M   | 70                | 10.5     | 1388            | 0         | I/II        | 1          | 0     | no  |
| 3  | normal        | F   | 72                | 7        | 1406            | 0         | I/II        | 0          | 0     | no  |
| 4  | normal        | F   | 65                | 19       | 1207            | 0         | 0           | 1          | 0     | no  |
| 5  | normal        | F   | 56                | 12       | 1416            | 0         | I/II        | n/a        | 0     | no  |
| 6  | normal        | M   | 61                | 6        | 1369            | 0         | 0           | 1          | 0     | no  |
| 7  | normal        | M   | 55                | 11.5     | 1448            | 0         | 0           | n/a        | 0     | no  |
| 8  | normal        | F   | 59                | 13       | 1166            | 0         | 0           | n/a        | 0     | no  |
| 9  | normal        | M   | 68                | 21       | 1330            | 0         | I/II        | 0          | 0     | no  |
| 10 | normal        | M   | 47                | 11       | 1333            | 0         | I/II        | n/a        | A     | no  |
| 11 | normal        | M   | 72                | 13.5     | 1320            | 0         | I/II        | 3          | A     | no  |
| 12 | normal        | F   | 46                | 12       | 1228            | 0         | 0           | n/a        | 0     | no  |
| 13 | normal        | F   | 65                | 22       | 1206            | 0         | I/II        | 1          | 0     | no  |
| 14 | normal        | M   | 67                | 15       | 1545            | 0         | I/II        | 2          | A     | no  |
| 15 | normal        | F   | 68                | 15       | 1151            | 0         | I/II        | 0          | 0     | no  |
| 16 | normal        | M   | 70                | 36       | 1755            | 0         | 0           | 0          | 0     | no  |

Abbreviations: #: case number, Normal diagnosed neurologically normal, F female, M male, PMI postmortem interval, ALS stage stages 0–4 semi-quantitatively assessed according to [14, 15]. Braak stage neurofibrillary tangle deposition according to [12, 13]. Thal phase amyloid deposition according to [108]. CERAD neuritic plaque deposition according to [76, 80]. LBD Lewy Body disease according to [75]. n/a data not available. no no LBD
were placed in a cool tray and left to cool to room temperature (~20 min). Slides were washed in 0.1 M Tris pH 7.6 and blocked in 0.1 M Tris pH 7.6 with 2% FBS. Primary antibodies, in 0.1 M Tris pH 7.6 with 2% FBS, were applied overnight at 4 °C. Sections were washed in 0.1 M Tris pH 7.6, blocked in Tris pH 7.6 with 2% FBS, and incubated with biotinylated IgG from mouse (1 in 1000, Vector labs #BA-2000) or rat (1 in 1000, Vector labs #BA-9401) for 1 h at room temperature. Slides were washed in 0.1 M Tris pH 7.6 and then 0.1 M Tris pH 7.6 with 2% FBS and incubated with an avidin-conjugated horseradish peroxidase (Vectastain ABC kit, #PK-6100) made up in Tris pH 7.6 with 2% FBS (1 h at room temperature). Slides were washed in Tris pH 7.6 and developed with Diaminiobenzidine (DAB) solution (Vector labs, SK-4105) for 8 min at room temperature. Slides were counterstained with Harris hematoxylin (30 s), washed in running tap water (10 min) dehydrated, cleared in xylene and mounted in cytoseal XYL (ThermoFisher, #8312–4). All Tris based washes were 5 min. Primary antibodies used were rat anti-phosphorylated (pS409/410) TDP-43 monoclonal antibody (1 in 500, [83]) and mouse anti-PAR, BSA free (1 in 500, Tulip Biolabs, #1020 N). Note, antigen retrieval and cooling steps were omitted for anti-PAR labelling. The anti-PAR antibody was first optimized by a serial dilution test (from 1 in 400 to 1 in 25,000). No signal was detected at 1 in 25,000 indicating that the

Table 2 Details of patients diagnosed with ALS-related neurological disease

| #  | Diagnosis | Sex | Age of Onset (yr) | Age at Death (yr) | Disease Duration (yr) | Mutation Status | PMI (hr) | Brain weight (g) | ALS Stage | Braak stage | Thal phase | CERAD LBD | LBD |
|----|-----------|-----|------------------|------------------|----------------------|----------------|---------|-----------------|-----------|-------------|-----------|-----------|-----|
| 17 | ALS       | M   | 41               | 42               | 1                    | –               | 8       | 1554            | 2         | V/II        | n/a       | 0         | no  |
| 18 | ALS       | M   | 71               | 76               | 5                    | –               | 23      | 1297            | 1         | V/II        | n/a       | A         | no  |
| 19 | ALS-D     | M   | 50               | 53               | 3                    | –               | 24      | 1422            | 2         | 0          | n/a       | 0         | no  |
| 20 | ALS-D     | F   | 50               | 51               | 1                    | –               | 4       | 1203            | 4         | V/II        | n/a       | 0         | no  |
| 21 | ALS       | M   | 43               | 46               | 3                    | –               | 5       | 1427            | 3         | V/II        | n/a       | 0         | no  |
| 22 | ALS       | F   | 79               | 81               | 2                    | –               | 10      | 1215            | 4         | III/IV      | n/a       | 0         | no  |
| 23 | ALS       | M   | 64               | 66               | 2                    | –               | 14      | 1427            | 2         | V/II        | n/a       | 0         | no  |
| 24 | ALS       | M   | 76               | 85               | 9                    | –               | 9       | 1041            | 1         | V/M         | n/a       | C         | diffuse neocortical |
| 25 | ALS       | F   | 73               | 75               | 2                    | –               | 8       | 1405            | 4         | V/II        | n/a       | A         | no  |
| 26 | ALS-D     | F   | 57               | 59               | 2                    | –               | 18      | 1125            | 4         | V/II        | n/a       | 0         | no  |
| 27 | ALS/PLS   | M   | 54               | 74               | 20                   | –               | 4       | 1169            | 1         | V/II        | n/a       | 0         | no  |
| 28 | ALS       | M   | 69               | 70               | 1                    | –               | 4       | 1135            | 1         | 0          | 0         | 0         | no  |
| 29 | ALS       | F   | 63               | 67               | 4                    | –               | 10      | 1384            | 2         | 0          | 0         | 0         | no  |
| 30 | ALS       | F   | 43               | 50               | 7                    | –               | n/a     | 1237            | 2         | 0          | 0         | 0         | no  |
| 31 | ALS       | F   | n/a              | 48               | n/a                  | ATXN2 (22/32)   | 5       | 1374            | 3         | 0          | n/a       | 0         | no  |
| 32 | ALS-D     | M   | n/a              | 78               | n/a                  | ATXN2 (22/27)   | 6       | 1300            | 4         | III/IV      | n/a       | B         | transitional |
| 33 | ALS       | F   | 64               | 67               | 3                    | ATXN2 (20/31)   | 19      | 1229            | 3         | V/II        | n/a       | 0         | no  |
| 34 | ALS       | M   | 63               | 65               | 2                    | ATXN2 (22/29)   | 7       | 1395            | 4         | III/IV      | n/a       | 0         | no  |
| 35 | ALS       | F   | 54               | 56               | 2                    | ATXN2 (22/27)   | 10      | 1426            | 1         | V/II        | n/a       | 0         | no  |
| 36 | ALS       | M   | 52               | 54               | 2                    | C9orf72         | 4       | 1536            | 3         | 0          | n/a       | 0         | no  |
| 37 | FTD       | F   | 47               | 54               | 7                    | C9orf72         | 12      | 813             | 4         | III/IV      | n/a       | 0         | no  |
| 38 | ALS-D     | M   | 55               | 57               | 2                    | C9orf72         | 9       | 1200            | 4         | III/IV      | n/a       | B         | no  |
| 39 | ALS-D     | M   | 54               | 57               | 3                    | C9orf72         | 15      | 1244            | n/a       | V/II        | n/a       | 0         | no  |
| 40 | ALS-D     | F   | 67               | 69               | 2                    | C9orf72         | 21      | 1079            | 4         | III/IV      | n/a       | B         | no  |
| 41 | ALS-D     | M   | 61               | 62               | 1                    | C9orf72         | 30      | 1240            | 4         | V/II        | n/a       | 0         | no  |
| 42 | ALS-D     | M   | 46               | 48               | 2                    | C9orf72         | 13      | 1309            | 4         | V/II        | n/a       | 0         | no  |
| 43 | ALS       | M   | 70               | 71               | 1                    | C9orf72         | 18      | 1221            | 2         | V/M         | 2         | B         | no  |

Abbreviations: #: case number. –: no known mutation in TARDBP, UBQLN2, ATXN2, and C9orf72. ATXN2 refers to an intermediate CAG-trinucleotide expansion in ATXN2 (pathologic repeat length is indicated in brackets). C9orf72 refers to a GGGGCC-hexanucleotide repeat expansion. ALS-D ALS with dementia. FTD frontotemporal degeneration. PLS primary lateral sclerosis. F female, M male. PMI postmortem interval. ALS stage stages 0–4 semiquantitatively assessed according to [14, 15]. Braak stage neurofibrillary tangle deposition according to [12, 13]. Thal phase amyloid deposition according to [108]. CERAD neuritic plaque deposition according to [76, 80]. LBD Lewy Body disease according to [75]. n/a data not available. no no LBD
secondary antibody was not contributing to the observed signal at higher primary concentrations. Dilution tests were performed on spinal cord tissue from 5 normal cases and 4 ALS cases.

Slides were coded and blinded and quantified by two researchers independently. For nuclear PAR scoring, 1–5 sections from every case were quantified and all the alpha motor neurons present in the anterior horns of each of section were scored for whether the nucleus was present and, if so, whether the nucleus stained for PAR. If all motor neurons with a nucleus were negative for PAR the score was 0. If 1 or more motor neurons with nuclei visible in the section were present and stained for nuclear PAR: a score of + was given if nuclear PAR was present in 1 motor neuron and ++ if more than 1 motor neuron stained for nuclear PAR. To determine the number of alpha motor neurons in ALS and normal spinal cord, motor neurons from one anterior horn from each case were counted. In the ALS anterior horn, there were 13.7±1.4 (SEM) alpha motor neurons with 4.0±0.4 (SEM) nuclei exposed. In the normal anterior horn, there were 19.5±1.4 (SEM) alpha motor neurons with 5.6±0.6 (SEM) nuclei exposed.

**Immunofluorescence and cell culture**

Human TDP-43-YFP cloned into pcDNA3.2 is described [29]. Standard cell culture and immunofluorescence techniques were used as described [73]. Briefly, COS-7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing high glucose and L-glutamine and sodium bicarbonate (Sigma-Aldrich, #D5796). 10% fetal bovine serum (Sigma-Aldrich, #F16178) and 1% penicillin-streptomycin (ThermoFisher, #15140122) at 37 °C with 5% CO₂. For immunofluorescence cells were present and stained for nuclear PAR: a score of + was given if nuclear PAR was present in 1 motor neuron and ++ if more than 1 motor neuron stained for nuclear PAR. To determine the number of alpha motor neurons in ALS and normal spinal cord, motor neurons from one anterior horn from each case were counted. In the ALS anterior horn, there were 13.7±1.4 (SEM) alpha motor neurons with 4.0±0.4 (SEM) nuclei exposed. In the normal anterior horn, there were 19.5±1.4 (SEM) alpha motor neurons with 5.6±0.6 (SEM) nuclei exposed.

**Results**

**Rat motor neuron cultures**

Mixed spinal cord cultures were prepared from rat and transfected with virus following previously established protocols [77, 78]. The titer of herpes simplex virus routinely used in our studies was 3–5×10⁷ plaque forming units (pfu)/ml [78]. The primary neuron cultures were infected 14 days in vitro (DIV) with herpes simplex virus (HSV) expressing either TDP-43 or LacZ. The inhibitor Veliparib, also called ABT-888 (Selleckchem, # S1004), or DMSO was added to the cell-culture medium at the indicated concentration at the time of infection. Media was changed 3-days post infection and cells were fixed and processed for immunofluorescence on day 5 of infection. Mouse anti-neurofilament-H, NF-H (1 in 1000, Biolegend #801703) and mouse AlexaFluor 488 (1 in 500, ThermoFisher, # A-21203) were used to identify neurons. Five images (10X magnification) were captured from each condition and remaining neuronal cell bodies were counted. Each condition was repeated three times, on three independent cultures. Statistics were performed in Graphpad 6 software.

**Statistics**

All data were analyzed in Graphpad Prism 6. To compare age at death between normal and ALS a Mann-Whitney Test was used. To compare disease duration between ALS disease cohorts a Kruskal-Wallis test was used. To compare cytoplasmic or nuclear PAR immunoreactivity between normal and ALS, or nuclear PAR between ALS and ALS-D cohorts a Fisher’s exact test was used. To compare nuclear PAR immunoreactivity between ALS-no mut, ALS-ATXN2 and ALS-c9, a Chi-square (Χ²) test was used. Cell culture and primary neuron experiments were repeated in triplicate and a mean (± SEM) is presented. One-way or two-way ANOVA followed by the appropriate post-hoc test was used to test for significance. Details of statistical tests used are in the associated figure legends. All experiments were repeated in triplicate unless otherwise stated. Data were considered statistically significant if \( p \leq 0.05 \), \( p \) values are marked * if \( p \leq 0.05 \), ** if \( p \leq 0.01 \), *** if \( p \leq 0.001 \) and **** if \( p \leq 0.0001 \).

**Study subjects, clinical characteristics and diagnosis**

We examined spinal cord tissue from a total of 43 patients; 16 were negative for any known neurological
disorder (9 male and 7 female) and are described as the normal cohort (Fig. 1a and Table 1). As we wanted to analyze motor neurons and phosphorylated TDP-43 inclusions in the ALS spinal cord, we selected cases which had large alpha neurons that also contained phosphorylated TDP-43 inclusions. Of the 27 selected disease cases (16 male and 11 female), 17 were diagnosed with ALS, 8 with ALS concomitant with dementia (ALS-D), 1 with ALS concomitant with primary lateral sclerosis (PLS) and 1 with frontotemporal degeneration (FTD) (Fig. 1b and Table 2), and are collectively described as the ALS-cohort. The median age of onset for the disease cohort was 59 yr., the median disease duration was 2 yr. There was no significant difference in the median age at death between the normal and ALS cohorts (65 yr. vs 62 yr., respectively) (Fig. 1c). Of the ALS cohort, 14 were negative for known mutations in TARDBP, UBQLN2, FUS, ATXN2 and C9orf72, 5 had an intermediate polyglutamine (polyQ) expansion (27–33 CAG repeats) in ATXN2 (ALS-ATXN2), and 8 cases had a G4C2-hexanucleotide repeat expansion in C9orf72 (ALS-c9) (Table 2). No data for disease onset was present for two ALS-ATXN2 cases. No significant difference was detected in this cohort for disease duration or age at death between ALS-no mut, ALS-ATXN2 and ALS-c9 (Fig. 1c-d).

Nuclear PAR is elevated in motor neurons of ALS spinal cord

To ascertain whether PAR activity was misregulated in disease, we examined the post-mortem spinal cord for immunoreactivity against PAR. We observed PAR in the nucleus and cytoplasm of motor neurons in spinal-cord tissue from both neurologically normal and ALS patients (Fig. 2a). Tissue sections were coded and blinded and examined for the presence of PAR in the motor neurons of the anterior horn. The severity of neuropathological markers such as phosphorylated TDP-43 are routinely graded on a semi-quantitative scale [14, 15]. We developed a semi-quantitative scale to score PAR immunoreactivity in motor neurons (0 not detectable; + detectable in 1 motor neuron; and ++ detectable in > 1 motor neuron) and examined staining in both the cytoplasm and nucleus. Our analysis revealed that 12 out of 14 of the neurologically normal cases and 27 out of 27 ALS cases presented with PAR in the cytoplasm of motor neurons (Fig. 2a-b and Tables 3 and 4). A Fisher’s exact test revealed no significant difference (p = 0.1329) between normal and ALS patients, indicating that cytoplasmic PAR was not significantly misregulated in this disease cohort. By contrast, nuclear PAR in the spinal cord motor neurons was detected in 3 out of 16 normal cases and in 24 out of 27 ALS cases (Fig. 2a and c, Tables 3 and 4). All cases that were negative for nuclear PAR presented with motor neurons with visible nuclei. A Fisher’s exact test between the normal and ALS cases revealed that motor neurons with nuclear PAR was significantly (p < 0.0001) associated with ALS. Additionally, the presence of nuclear PAR in the motor neurons of the spinal cord from ALS-no mut, ALS-ATXN2 and ALS-c9orf72 did not differ (X² (3) = 0.1436, p = 0.9861) (Table 4). Given the reported morphological differences in TDP-43 aggregates in the anterior cingulate of ALS vs ALS-D patients [106], we compared nuclear PAR in the motor neurons between these two disease subtypes and observed no statistical significance (p = 1.0). It is important to note that the normal anterior horn compared to

---

**Fig. 1** Case demographics. a. Spinal cord tissue from 16 patients with no history of neurodegenerative disease was examined in this study; 7 were female and 9 were male. b. The spinal cord from 27 patients diagnosed with ALS were examined in this study; 11 were female and 16 were male. c. There was no statistical difference in the age of death between the normal and ALS patients. The graph represents the median with interquartile range. A Mann-Whitney test was used to test for significance. d. Compared to the no-mutation carriers, the presence of a mutation in C9orf72 or an intermediate polyQ expansion in ATXN2 did not cause a significant change in disease duration in these pre-selected cohorts. The graph represents the median with interquartile range. A Kruskal-Wallis test was used to test for significance.
ALS-all anterior horn had significantly more motor neurons (19.5±1.4 vs 13.7±1.4 (SEM) \( p = 0.0081 \)) and significantly more visible nuclei (5.6±0.6 vs 4.0±0.4 (SEM) \( p = 0.0393 \)). It is likely that the severity of nuclear PAR staining in ALS is under represented in our analyses. Combined, our data indicate that the motor neurons of the post-mortem spinal cord from ALS patients exhibit significantly elevated levels of nuclear PAR.

Motor neurons do not have cytoplasmic inclusions of PAR

To gain further insight into the pattern of PAR immunoreactivity in the ALS spinal cord, we determined whether PAR formed neuronal cytoplasmic inclusions in neurons that contained phosphorylated TDP-43. Serial sections of spinal cord from 4 ALS patients were immunostained with either an antibody that selectively detects TDP-43 phosphorylated at serines 409/410 (pS409/410) or with an antibody that detects PAR. In all 4 cases (case numbers: 22, 23, 25 and 26) cytoplasmic inclusions of phosphorylated TDP-43 were present in the motor neurons (Fig. 3a). In serial sections, we found no evidence of PAR aggregation in the cytoplasm in the neurons in which phosphorylated TDP-43 was detected (Fig. 3a). Additionally, in these 4 cases (22, 23, 25 and 26) nuclear PAR

**Fig. 2** ALS motor neurons have elevated levels of nuclear PAR. a. Spinal cord sections from a neurologically normal case showing a motor neuron with no nuclear PAR immunoreactivity (arrow). An ALS-no mut case with three motor neurons with nuclear PAR (arrows). An ALS-ATXN2 case with two motor neurons presenting with nuclear PAR (arrows). An ALS-c9 case with one motor neuron with nuclear PAR (arrow). Sections were immunostained for PAR and counterstained with Hematoxylin. b. The presence of cytoplasmic PAR in the motor neurons of the spinal cord was quantified on a semi-quantitative scale (0 no detectable cytoplasmic PAR; + cytoplasmic PAR detected in 1 motor neuron; ++ cytoplasmic PAR detected in > 1 motor neuron), see also Tables 3 and 4. The data was charted as a percentage. c. The presence of nuclear PAR in the motor neurons of the spinal cord was quantified on a semi-quantitative scale (0 no detectable nuclear PAR; + nuclear PAR detected in 1 motor neuron; ++ nuclear PAR detected in > 1 motor neuron), see also Tables 3 and 4. The data were charted as a percentage. Slides were fully blinded and examined independently by two researchers, images for figures were captured with a 20X objective and an optivar magnification of 1.6.
PAR was present in motor neurons, and in serial sections none of those motor neurons displayed phosphorylated TDP-43 pathology (Fig. 3b). These data indicate that nuclear PAR occurred in motor neurons that have not developed phosphorylated TDP-43 pathology.

**Veliparib suppresses the formation of stress-induced foci of TDP-43**

Since nuclear PAR was detected in motor neurons of the ALS spinal cord, the activity of the nuclear PARPs may be activated in disease. There are three nuclear PARP enzymes: PARP-1, PARP-2, and also PARP-3, which is a monoa(ADP-ribose) transferase [41, 48, 60]. The antibody used to detect PAR recognizes PAR chains of 20 or more ADP-ribose subunits [52], suggesting that the PAR detected in the ALS spinal cord (see Figs. 2 and 3) is generated from PARP-1 or PARP-2 (collectively known as PARP-1/2). Small-molecule inhibitors of PARP-1/2 activity have been pursued as cancer therapeutics in more than 300 FDA-approved clinical trials [54, 102]. We thus sought to determine if PARP-1/2 inhibition could be of potential therapeutic value to ALS.

In cells, TDP-43 can be induced to aggregate and localize to cytoplasmic stress granules. It has been reported that the PARP-1/2 inhibitor, Veliparib, inhibits the formation cytoplasmic stress granules [23, 49]. We determined the efficacy of Veliparib to mitigate the formation of arsenite-induced TIAR-labelled stress granules in COS-7 cells (Fig. 4a). Upon exposure to 0.25 mM sodium arsenite, the percentage of cells with TIAR-labelled stress granules increased from 6±1% to 29±2% (SEM) (Fig. 4b-c). Co-treatment with 10 μM Veliparib reduced the percentage of cells with arsenite-induced TIAR-labelled stress granules to 9±1% (SEM) (Fig. 4b-c).

To examine the efficacy of Veliparib to mitigate cytoplasmic aggregation of TDP-43 in COS-7 cells, we exogenously expressed TDP-43-YFP. Normally, TDP-43-YFP was diffusely nuclear, however upon exposure to 0.25 mM sodium arsenite the percentage of cells with cytoplasmic TDP-43-YFP foci increased from 3±1% to 30±1% (SEM) (Fig. 4d-e). Co-treatment with Veliparib significantly reduced the percentage of cells with arsenite-induced TDP-43-YFP foci to near control levels (5±1% (SEM)) (Fig. 4d-e). These data suggest that in response to arsenite exposure, PARP-1/2 activity regulates stress-granule formation and stress-induced TDP-43 aggregation in the cytoplasm.

**Veliparib mitigates TDP-43 toxicity in primary spinal cord neurons**

Since Veliparib inhibited the accumulation of stress-induced TDP-43 foci in the cytoplasm, we queried whether this treatment could impact the toxicity of TDP-43 to primary spinal cord cultures. To address this question, we developed a toxicity assay in mixed spinal-cord cultures isolated from rat embryos (Fig. 5a).

The primary spinal cord cultures were virally infected with an attenuated herpes simplex virus expressing a LacZ control or of TDP-43. The cultures were maintained for 5d post infection, after which they were immunostained for the neuronal specific marker Neurofilament-H (NF-H) and the remaining NF-H-labeled cell bodies were imaged and quantified. In control conditions (LacZ), we observed an average of 102±5.6 (SEM) neuronal cell bodies (Fig. 5b-c). Infection with TDP-43 at 0.25×, 0.5× and 1× resulted in a dose-sensitive loss of neurons (76±2.2, 63±2.4 and 38±2.4 (SEM) neuronal cell bodies respectively) (Fig. 5b-c), indicating that virally expressed TDP-43 results in neuronal cell loss in rat spinal cord cultures.

To determine if Veliparib was effective at mitigating TDP-43-associated neuronal degeneration, we first examined spinal cord cultures infected with the LacZ control and treated with either DMSO or with 1 μM or 5 μM Veliparib. These controls revealed that Veliparib had no deleterious effects on the mixed spinal cord cultures at the concentrations tested (Fig. 5b-c). We then compared rat spinal cord cultures infected with TDP-43 and co-treated with DMSO or 1 μM or 5 μM Veliparib. Notably, treatment with 5 μM Veliparib protected the primary neurons such that there was no significant difference in the number of neuronal cell bodies, at all infection ratios of TDP-43 compared to the DMSO.
Table 4 PAR immunoreactivity in patients diagnosed with neurological disease

| #  | Diagnosis | Mutation Status | Region analyzed | PAR in MN nuclei | PAR in MN cytoplasm |
|----|-----------|-----------------|----------------|------------------|---------------------|
| 17 | ALS       | –               | cervical       | +                | ++                  |
| 18 | ALS       | –               | lumbar         | ++               | ++                  |
| 19 | ALS       | –               | cervical       | ++               | ++                  |
| 20 | ALS-D     | –               | lumbar         | ++               | ++                  |
| 21 | ALS       | –               | lumbar         | ++               | ++                  |
| 22 | ALS       | –               | lumbar         | ++               | ++                  |
| 23 | ALS       | –               | lumbar         | 0                | ++                  |
| 24 | ALS       | –               | cervical       | +                | ++                  |
| 25 | ALS       | –               | cervical       | +                | ++                  |
| 26 | ALS-D     | –               | cervical       | ++               | ++                  |
| 27 | ALS/PLS   | –               | cervical       | +                | ++                  |
| 28 | ALS       | –               | cervical       | 0                | ++                  |
| 29 | ALS       | –               | lumbar         | ++               | ++                  |
| 30 | ALS       | –               | cervical       | +                | ++                  |
| 31 | ALS       | ATXN2 (22/32)   | cervical       | ++               | ++                  |
| 32 | ALS-D     | ATXN2 (22/27)   | cervical       | ++               | ++                  |
| 33 | ALS       | ATXN2 (20/31)   | thoracic       | ++               | ++                  |
| 34 | ALS       | ATXN2 (22/29)   | lumbar         | ++               | ++                  |
| 35 | ALS       | ATXN2 (22/27)   | cervical       | 0                | ++                  |
| 36 | ALS       | C9orf72         | cervical       | ++               | ++                  |
| 37 | FTD       | C9orf72         | cervical       | ++               | ++                  |
| 38 | ALS-D     | C9orf72         | cervical       | ++               | ++                  |
| 39 | ALS-D     | C9orf72         | thoracic       | 0                | ++                  |
| 40 | ALS-D     | C9orf72         | thoracic       | ++               | ++                  |
| 41 | ALS-D     | C9orf72         | cervical       | +                | ++                  |
| 42 | ALS-D     | C9orf72         | lumbar         | ++               | ++                  |
| 43 | ALS       | C9orf72         | sacral         | +                | ++                  |

Abbreviations: #: case number. -: No known mutation in TARDBP, UBOQNL2, ATXN2, and C9orf72. ATXN2 refers to an intermediate CAG-trinucleotide expansion in ATXN2 (pathologic repeat length is indicated in brackets). C9orf72 refers to a GGGGCC-hexanucleotide repeat expansion. ALS-D ALS with dementia, FTD frontotemporal degeneration, PLS primary lateral sclerosis, PAR poly(ADP-ribose), MN motor neuron

Fig. 3 PAR does not form protein aggregates in the cytoplasm of motor neurons. a. Serial sections from ALS spinal cord tissue were stained for either PAR or phosphorylated TDP-43 (pS409/10). Motor neurons with phosphorylated TDP-43 aggregates did not also have cytoplasmic aggregates labelled with PAR. Arrowheads indicate the same neurons in each serial section. Scale bar: 50 μm. b. Serial sections of ALS spinal cord tissue were stained for either PAR or phosphorylated TDP-43 (pS409/10). The motor neurons shown with elevated nuclear PAR did not have cytoplasmic aggregates of phosphorylated TDP-43. Arrowheads indicate the same neuron in each section. Arrows indicate neuron with nuclear PAR. Scale bar: 50 μm
control (Fig. 5b-c). The neuronal processes appeared retained although not to the level of the control (Fig. 5c). These studies cannot determine whether the neurons or astrocytes account for TDP-43-associated neuronal loss or for the beneficial action of Veliparib. However, small molecule inhibition of PARP-1/2 is effective in mitigating TDP-43-associated neuronal loss in these spinal cord cultures, and could have therapeutic utility for ALS and other TDP-43-associated diseases.

Discussion
Our data indicate that ALS is associated with elevated nuclear PAR in the motor neurons of the spinal cord in all genetic backgrounds tested (no mutation, intermediate polyQ expansion in ATXN2 or C9orf72 mutation). We show that Veliparib, an inhibitor of nuclear PARP-1/2 activity, mitigates the formation of stress-induced cytoplasmic aggregates of TDP-43 in mammalian cells. We extend this finding to show that treating rodent spinal-cord cultures with Veliparib mitigates TDP-43-induced neuronal cell loss. Collectively, our data implicate the misregulation of nuclear PARP activity in ALS and highlight PARP-1/2 inhibitors as potential compounds for further therapeutic research.

In the early stages of ALS some patients will present with symptoms of neuronal hyperexcitability such as fasciculation and cramp [7, 111]. In support of hyperexcitability as a physiological mechanism, glutamate, the major excitatory neurotransmitter in the CNS, is elevated in the cerebrospinal fluid of ALS patients [93, 94, 101, 103]. Notably, PARP-1 activation has been implicated in mediating the response to glutamate-induced neurotoxicity in animal and cellular assays [5, 24, 113, 116]. Our neuropathologic analyses demonstrate that long-chained PAR polymers are present at elevated levels in the motor-neuron nuclei of the ALS spinal cord.

![Fig. 4 Small molecule inhibition of PARP-1/2 reduces the formation of stress-induced TDP-43 foci in mammalian cells.](image)

- **a** Veliparib is a small molecule inhibitor of PARP-1/2 activity reported to inhibit the formation of G3BP1-labelled foci in the cytoplasm upon UV treatment [49].
- **b** Exposure to arsenite leads to the formation of TIAR-labelled stress granules in the cytoplasm (arrows). Co-treatment with Veliparib inhibits the formation of TIAR-labelled stress granules. COS-7 cells transfected with TDP-43-YFP were immunostained for TIAR and counterstained with Hoescht. Cells were imaged for TIAR and Hoescht.
- **c** Cells were quantified for the presence of cytoplasmic TIAR-labelled stress granules. Mean (± SEM) is presented. One-way ANOVA followed by a Tukey's test was used for significance.
- **d** Under normal conditions (ctrl), TDP-43-YFP diffusely localizes to the cytoplasm of COS-7 cells. Upon treatment with arsenite, TDP-43-YFP forms foci in the cytoplasm (arrows). The formation of cytoplasmic TDP-43-YFP foci is inhibited by treatment with Veliparib. Cells were counterstained with Hoescht.
- **e** Veliparib reduces the accumulation of TDP-43-YFP foci in the cytoplasm. Cells were quantified for the presence of cytoplasmic TDP-43-YFP foci. Mean (± SEM) is presented. One-way ANOVA (p = 0.0002) followed by a Tukey's test was used for significance.
- **f** Hypothetical schematic showing that inhibition of PARP-1/2 activation by Veliparib inhibits the formation of stress-induced TDP-43-YFP foci.
finding implicates activation of the nuclear PARP enzymes (PARP-1 and PARP-2). PARP-1 is the most abundant and the most active following stress [27, 67]. The downstream consequence of PARP-1 activation leads to the propagation of several stress-associated pathways [1, 21, 34, 63]. Upon over activation of PARP-1, the enzyme elicits a cell death mechanism, which is characterized by cleavage of PARP-1 [34, 50, 100]. Previous reports indicate that PARP-1 protein and cleaved PARP-1 is elevated in ALS [32, 56, 57]. Combined with our data that demonstrate PAR is elevated in ALS motor neurons it could be that PARP-1/2 is activated by localized glutamate excitotoxicity and that the motor neurons may be undergoing PAR-mediated cell death.

PARP-1/2 also plays a role in nuclear and cytoplasmic protein localization. For example, upon inflammatory stress, PARP-1/2 promotes nuclear retention of the transcription factor High mobility group B1 (HMGBP1) [1]. Under extreme conditions of DNA damage PAR polymers produced by PARP-1 are released into the cytoplasm and bind to Apoptosis Inducing Factor (AIF) in the mitochondria to promote translocation of AIF and macrophage migration inhibitory factor (MIF) to the nucleus to elicit a programmed cell death mechanism [34, 113, 114]. PARP-1 activity has also been implicated in signaling to PARP-12 in the cytoplasm to regulate the formation of cytoplasmic stress granules [23, 49]. Here we show that treatment with PARP-1/2 inhibitor, Veliparib, mitigates
the formation of stress-induced aggregates of TDP-43 in the cytoplasm, suggesting that PARP-1/2 activity impacts cytoplasmic aggregation of TDP-43. Indeed, nuclear PAR was not detected in neurons harboring phosphorylated TDP-43 aggregates, suggesting that the PARP-1/2 activation observed in ALS motor neurons may occur at earlier stages in neuron compromise. We suggest that PARP-1/2 activation may precede the exit of TDP-43 from the nucleus and the subsequent formation of cytoplasmic TDP-43 aggregates.

Of the ~5% of ALS cases that lack TDP-43 pathology (TDP-43-negative ALS), a subset is the result of a mutation in FUS (fused in sarcoma) [46, 61, 112]. FUS is an RNA-binding protein that is recruited to sites of DNA damage by PARP-1 [3, 81, 96] and at high concentrations, the PARP-1/2 inhibitor Veliparib can promote the mislocalization of nuclear FUS-GFP to the cytoplasm [81]. A second notable gene mutated in TDP-43-negative ALS is SOD1 (superoxide dismutase 1) [69]. Curiously, PARP-1 protein is elevated in spinal cord astrocytes in SOD1 G93A transgenic mice [22] and is cleaved in SOD-1 cellular models [59]. However, pharmacological treatment with a PARP-1 inhibitor had no effect on the lifespan or motor performance of the SOD1 G93A transgenic mouse [6]. It is possible that PARP-1/2 regulation of neuronal demise is selectively involved in TDP-43-positive ALS. In support of PARP-1 mediated regulation of the central nervous system in disease it has been shown that PARP-1 overactivation leads to neuronal degeneration in Drosophila [43]. PARP-1 activation has also been linked to Alzheimer’s (AD), Parkinson’s (PD) and ischemic stroke [19, 31, 51, 71, 72, 79], and the use of PARP-1/2 inhibitors is beneficial to mouse models of these diseases [2, 20, 25, 30, 87, 105, 109, 115]. These data indicate that, despite dampening the DNA damage response, PARP-1/2 inhibition provides improved neuronal integrity and function in these animal models of disease. To assign therapeutic potential of PARP-1/2 inhibitors and understand potential side effects, it will be imperative to examine additional ALS subtypes and associated diseases.

A range of small-molecule inhibitors of PARP-1/2, including the inhibitor used here, have been developed for clinical application as they sensitize cancer cells to cell death. Moreover, some have been reported to cross the blood-brain barrier [16, 17, 33]. These inhibitors have been tested in hundreds of FDA-approved clinical trials of various cancers and there is a wealth of information on the pharmacokinetics, pharmacodynamics, and toxicity of these compounds that would be beneficial in repurposing them for alternative diseases [11, 54, 102]. We previously implicated inhibitors of PARP-5a and PARP-5b, collectively known as PARP-5a/5b, in reducing the cytoplasmic aggregation of TDP-43, without having an effect on the percentage of cells with G3BP1-positive stress granules [73]. PARP-5a/5b inhibitors are also in development as cancer therapeutics [42, 62, 70]. It is possible that PARP-1/2 more broadly effects stress granule formation and stress-induced protein aggregation, while PARP-5a/5b may act on select proteins in stress signaling.

**Conclusion**

Our study implicates the activation of PARP-1/2 in the motor neuron nuclei of the ALS spinal cord. We show that treatment with Veliparib, a PARP-1/2 inhibitor, reduces stress-induced accumulation of TDP-43 in the cytoplasm of mammalian cells. Furthermore, we show that Veliparib can mitigate the toxic effect of virally expressed TDP-43 in rodent spinal cord cultures. Currently, the mechanisms that may link TDP-43 and PARP-1/2 in cell culture models and human disease remains to be elucidated. We suggest that the PARP superfamily is an area that should be explored further in ALS therapeutics.

**Funding**

This work was funded by grants from the Life Extension Foundation (JS), ALS Association (US), Department of Biochemistry and Biophysics Pilot Grant (US), Target ALS (JS and NMB), the Glenn Foundation (NMB), the Robert Packard Center for ALS Research at Johns Hopkins (JS), AG-017586 (VMO), and the NIH: R01NS095746–01 (RGK), R21NS093439 (RGK), S21NS087077–02 (RGK), R01GM099836 (US), R21NS090205 (US), P30AG10124 (VMYL and JQT), P01AG17586 (VMYL and JQT), R01NS095793 (EBL) 5R01NS073660 (NMB), R35NS097275 (NMB).

**Availability of data and materials**

All raw data presented are available upon reasonable request.

**Authors’ contributions**

LM conceived and designed experiments, analyzed data and supervised the research. EBL and NMB wrote the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Informed consent was obtained from next of kin in accordance with institutional review board guidelines of the University of Pennsylvania.

**Consent for publication**

All authors consent to publication.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA. 2. Department of Neurology, Children’s Hospital of Philadelphia, Joseph Stokes Jr. Research Institute, Philadelphia, PA 19104, USA. 3. Present address: Les Turner ALS Center at Northwestern Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. 4. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, PA 19104, USA. 5. Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 6. Translational Neuropathology Research Laboratory, 605B Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104, USA.
References

1. Abd Elmageed ZY, Naura AS, Errami Y, Zerfaoui M (2012) The poly(ADP-ribose): polymerase (PARPs): new roles in intracellular transport. Cell Signal 24:1–8. https://doi.org/10.1016/j.cellsig.2011.07.019

2. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, Szabo C, Endres M (2007) Antioxidant properties of SIRT1, PARP-1, and -2 in the regulation of cerebral ischemia. J. Neurochem 106:2153–2160. https://doi.org/10.1111/j.1471-4159.2007.04762.x

3. Altmeyer M, Neelsen KJ, Teloni F, Pozdnuyakova I, Pellegrino S, Groffe M, Rask MB, Streicher W, Jungmichel S, Nielsen ML et al (2015) Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). Nat Commun 6:8088. https://doi.org/10.1038/ncomms9088

4. Anderson P, Kedershia N (2008) Stress granules: the Taro of RNA triage. Trends Biochem Sci 33:141–150. https://doi.org/10.1016/j.tibs.2007.12.003

5. Andradi SA, Kang HC, Haince JF, Lee YI, Zhang J, Chi Z, West AB, Koehler RC, Poireir GG, Davison TM et al (2011) Kldn protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymerase-induced cell death. Nat Med 17:692–699. https://doi.org/10.1038/nm.2387

6. Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, Szabo C, Beal MF (2001) Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethyllepinephrine, trientine, and lipic acid in transgenic ALS mice. Exp Neurol 168:419–424. https://doi.org/10.1006/exnr.2001.7633

7. Baie JS, Simon NG, Menon P, Vuric S, Kienman MC (2013) The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurosci 19:655–74. https://doi.org/10.1016/j.jocn.2013.9.265

8. Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing JH, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase: poly(ADP-ribose)-polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J Pharmacol Exp Ther 310:985–949. https://doi.org/10.1124/jpet.103.048934

9. Chiarugi A (2005) Poly(ADP-ribose)lation and stroke. Pharmacol Res 52:15–24. https://doi.org/10.1016/j.phrs.2005.02.018

10. Chiarugi A, Melli E, Calvani M, Picca R, Baronti R, Camaioni E, Costantino G, Marinozzi M, Pellegrini-Giampietro DE, Pellicciani R et al (2003) Novel isoquinolinolinoine-derived inhibitors of poly(ADP-ribose) polymerase-1: in vivo anti-neoplastic activity and safety profile in a xenograft model of glioblastoma multiforme. Eur J Pharmacol 471:149–158. https://doi.org/10.1016/j.ejphar.2003.08.050

11. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA (1997) Ischemic cell death can be blocked by specific inhibition of poly(ADP-ribose) polymerase. J Cereb Blood Flow Metab 17:1143–1151. https://doi.org/10.1093/hmg/ddv104

12. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. https://doi.org/10.1038/nature03446

13. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandeim NJ, Xie SX, Kwong LK, Elman L, McCluskey L et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66:180–189. https://doi.org/10.1001/archneurol.2008.558

14. Gibson BA, Kraus WL (2012) New insights into the molecular and functional roles of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13:411–424. https://doi.org/10.1038/nrm3376

15. Riluzole to Edaravone: revising the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutic agents. Clin Pharmacokinet. https://doi.org/10.1007/s40262-018-0655-4

16. Dawson VL, Davison TM (2004) Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 36:287–294. https://doi.org/10.1023/B:JOBB.0000041755.22613.8d

17. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J et al (2011) Expanded GGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Nature 472:245–256. https://doi.org/10.1038/nature09711

18. Elder AC, Kim HJ, Hart MP, Chen-Fo-Tskin AK, Johnson BS, Fang X, Armakola M, Geier F, Greene R, Lu MM et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069–1075. https://doi.org/10.1038/nature09320

19. Endres M, Scott GS, Salzman AL, Kun E, Moskowitz MA, Szabo C (1998) Protective effects of 5-iodo-6-amino-1,2-benzopyrene, an inhibitor of poly(ADP-ribose) synthetase against peroxynitrite-induced glial damage and stroke development. Eur J Pharmacol 351:377–382

20. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA (1997) Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. J Cereb Blood Flow Metab 17:1143–1151. https://doi.org/10.1093/hmg/ddv104

21. Farag MA, Konopka A, Soo KY, Ito D, Atkin JD (2017) The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum Mol Genet 26:2882–2896. https://doi.org/10.1093/hmg/ddx170

22. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. https://doi.org/10.1038/nature03446

23. Fautok AA, Dawson VL, Davison TM (2014) Parthenatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 171:2000–2016. https://doi.org/10.1111/bph.12416

24. Finelli MJ, Liu XX, Wu Y, Oliver PL, Davies KE (2015) Oxl1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations. Hum Mol Genet 24:3529–3544. https://doi.org/10.1093/hmg/ddv104

25. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandeim NJ, Xie SX, Kwong LK, Elman L, McCluskey L et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66:180–189. https://doi.org/10.1001/archneurol.2008.558

26. Fasino DA, Kraus WL (2012) New insights into the molecular and functional roles of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13:411–424. https://doi.org/10.1038/nrm3376
of adenosine A2a and Trk receptors. J Neurosci 26:9250–9263. https://doi.org/10.1523/JNEUROSCI.1856-06.2006
78. Mojsov-Petrovic J, Nedisnyk N, Boccitto M, Mano I, Georgiades SN, Zhou W, Liu Y, Neve RL, Taylor JP, Driscoll M et al (2009) FOXXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci 29:8236–8247. https://doi.org/10.1523/JNEUROSCI.1805-09.2009
79. Moroni F, Meli E, Peruginelli F, Chiarugi A, Cozzi A, Picca R, Romagnoli P, Pellicciani R, Pellegrini-Gambari DE (2001) Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 8:921–932. https://doi.org/10.1038/sdd0409904
80. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, McGurk D, Goto J, O'Regan JP, Deng HX et al (1993) Mutations in Cu/Zn superoxide dismutase 1 are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62. https://doi.org/10.1038/362050a0
81. Naumann M, Pal A, Goswami A, Lojevski J, Xaptok J, Velhov A, Naujok M, Gunther R, Jin M, Stanislovsy N et al (2018) Impaired DNA damage response signaling by p53NLS-mutations leads to neurodegeneration and FUS aggregation. Nat Commun 9:335. https://doi.org/10.1038/s41467-017-02299-1
82. Neffussy B, Drory VE (2010) Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA J 1:329–341. https://doi.org/10.1016/j.epma.2010.0027-6
83. Neumann M, Kwon LK, Lee EB, Kriemmer E, Flaten A, XU Y, Forman MS, Troost D, Ketzschmar HA, Trojanowski JQ et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117:137–149. https://doi.org/10.1007/s00401-008-0477-9
84. Neumann M, Kwon LK, Truax AC, Vannassenhove H, Ketzschmar HA, Van Deelen VM, Clark CM, Grossman M, Miller BL, Trojanowski JQ et al (2007) TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol 66:173–183. https://doi.org/10.1097/00005210-200704000-00002
85. Neumann M, Sampathu DM, Kwon LK, McSweeny MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133. https://doi.org/10.1126/science.1134108
86. Oliver PL, Finelli MJ, Edwards B, Bitoun E, Becker EB, Cheeseman McGurk D, Goto J, O'Regan JP, Deng HX et al (1993) Mutations in Cu/Zn superoxide dismutase 1 are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62. https://doi.org/10.1038/362050a0
87. Rulten SL, Rotheray A, Grundy G, Moore DA, Gomez-Herreros F, Gunther R, Jin M, Stanslovsy N et al (2016) Abnormal excitation amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 78:18–25. https://doi.org/10.1002/ana.20805
88. Rothstein JD (2017) Edaravone: a new drug approved for ALS. Cell 171:725. https://doi.org/10.1016/j.cell.2017.10.011
89. Rothstein JD, KOND R, Chaudhry V, Clasgow L, Combrall DR, Coyle JT, Drachman DB (1991) Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann Neurol 30:224–225. https://doi.org/10.1002/ana.40300223
90. Rothstein JD, Tsai G, Kund RW, Clasgow L, Combrall DR, Drachman DB, Pestronk A, Stach BL, Coyle JT (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28:18–25. https://doi.org/10.1002/ana.400280106
91. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344:1688–1700. https://doi.org/10.1056/NEJM200105313442207
92. Rutten SL, Rotheray A, Green RL, Grundy GJ, Moore DA, Gomez-Herreros F, Hafezparast M, Caldecott KW (2014) PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage. Nucleic Acids Res 42:307–314. https://doi.org/10.1093/nar/gkt935
93. Savada H (2017) Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother 18:735–738. https://doi.org/10.1080/14656566.2017.1319937
94. Saxena S, Cabry E, Caroni P (2009) A role for motoneuron subtype-selective ER stress in disease manifestations of ALS5 mice. Nat Neurosci 12:627–636. https://doi.org/10.1038/nn.2297
95. Schreiber V, Dantzer F, Arne JC de, Muceta G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517–528. https://doi.org/10.1038/nrm1963
96. Shah GM, Shah RG, Poirier GG (1996) Different cleavage pattern for processing protein, cause familial amyotrophic lateral sclerosis type 6. Neurotherapeutics 12:317–329. https://doi.org/10.1007/s13167-010-0027-0
97. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell H (1995) CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 4:209–216
98. Sonnenblick A, de Azambuja E, Azim HA, Fricott C (2015) An update on PARP inhibitors—moving to the adjuvant setting. Nat Rev Clin Oncol 12:227–241. https://doi.org/10.1038/nrclinonc.2014.163
99. Speux-Varoquaux O, Benson G, Lacombré L, Salachas F, Pradat PF, le Forestier N, Marouan A, Dib M, Meiningier V (2002) Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 193:73–78
100. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall J, Williams KL, Buratti E et al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668–1672. https://doi.org/10.1126/science.1154584
101. Takahashi K, Greenberg JH, Jackson P, Maclin K, Zhang J (1997) Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17:1137–1142. https://doi.org/10.1038/neurolong.2010.00001
102. Tan RH, Yang Y, Kim WS, Dobson-Stone C, Kwok JB, Kienman MC, Halliday GM (2017) Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Acta Neuropathol Commun 5:76. https://doi.org/10.1186/s41467-017-0480-2
103. Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to mechanism. Nature 539:197–206. https://doi.org/10.1038/nature20413
104. Thai DR, Rub U, Orantes M, Braak H (2002) Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800
105. Turunc Bayrakdar E, Uyanikgil Y, Kanit L, Koylu E, Yalcin A (2014) Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17:1137–1142. https://doi.org/10.1038/neurolong.2010.00001
114. Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, Poirier GG, Dawson VL, Dawson TM (2011) Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal 4:ra20. https://doi.org/10.1126/scisignal.2000902

115. Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T (2010) Poly(ADP-ribose) polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J Neurosci Res 88:1522–1536. https://doi.org/10.1002/jnr.22310

116. Zhang J, Dawson VL, Dawson TM, Snyder SH (1994) Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263:687–689

117. Zhang K, Daigle JG, Cunningham MW, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F et al (2018) Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell 173:958–971 e917. https://doi.org/10.1016/j.cell.2018.03.025